First Anticoagulant Approved to Treat Symptomatic VTE in Pediatric Patients
The FDA has approved Fragmin, a low molecular weight heparin, for the treatment of symptomatic venous thromboembolism to reduce the recurrence of VTE in pediatric patients 1 month of age and older.